Mangalam Drugs and Organics Receives NCLT Approval for Merger Scheme

1 min read     Updated on 15 Oct 2025, 03:46 PM
scanx
Reviewed by
Ashish ThakurScanX News Team
Overview

Mangalam Drugs & Organics Limited (MDOL) received an NCLT order admitting a petition for a merger scheme involving Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited. The petition was presented on September 23, 2025, with a final hearing scheduled for December 16, 2025. NCLT has directed notices to be issued to various statutory authorities, giving them 30 days to submit representations. MDOL will keep stock exchanges informed of further developments.

22068983

*this image is generated using AI for illustrative purposes only.

Mangalam Drugs & Organics Limited (MDOL) has taken a significant step forward in its corporate restructuring plans. The company recently received a certified true copy of an order from the National Company Law Tribunal (NCLT) Mumbai Bench, admitting a petition for a scheme of merger by absorption.

Key Details of the Merger Scheme

The merger scheme involves the following entities:

  • Mangalam Laboratories Private Limited
  • Shri JB Pharma Private Limited
  • Mangalam Drugs and Organics Limited

NCLT Proceedings

  • Petition Presentation Date: September 23, 2025
  • Admitting Bench: NCLT Bench-III
  • Bench Members:
    • Ms. Lakshmi Gurung (Member Judicial)
    • Sh. Hariharan Neelakanta Iyer (Member Technical)
  • Final Hearing Date: December 16, 2025

Regulatory Notifications

The NCLT has directed notices to be issued to various statutory authorities, including:

  • Central Government
  • Income Tax Authorities
  • Reserve Bank of India
  • Securities and Exchange Board of India
  • Other relevant regulators

These authorities have been given 30 days to submit their representations regarding the merger scheme.

Next Steps

MDOL has committed to keeping the stock exchanges informed of any further material developments in this matter. The company will need to await the final hearing scheduled for December 16, 2025, where the NCLT will consider the merger scheme for final approval.

Implications for Investors

While the admission of the petition is a positive step towards the company's restructuring plans, investors should note that the final approval is still pending. The outcome of the merger could potentially impact the company's operations, financial structure, and market position.

Mangalam Drugs and Organics Limited continues to demonstrate its commitment to transparency by promptly disclosing this development to the stock exchanges. Investors and stakeholders are advised to keep a close watch on further announcements as the merger process progresses.

Historical Stock Returns for Mangalam Drugs & Organics

1 Day5 Days1 Month6 Months1 Year5 Years
-1.24%+0.68%-8.14%-12.38%-42.38%-51.49%
Mangalam Drugs & Organics
View in Depthredirect
like17
dislike

Manglam Group Launches ₹100 Crore Redevelopment Project in Mumbai's Borivali

2 min read     Updated on 06 Oct 2025, 05:52 PM
scanx
Reviewed by
Jubin VergheseScanX News Team
Overview

Manglam Group has launched its first redevelopment project in Mumbai, Manglam Rajanigandha, in Borivali (West) with a ₹100 crore investment. The project, expected to generate ₹150 crore in revenue, will offer 80 two-bedroom apartments across 80,000 sq. ft. Half of the units will be allocated to existing tenants. The development includes amenities like landscaped green zones, a fitness center, and a jogging track. Homeowners will receive lifetime membership at the Mandapeshwar Civic Federation Gymkhana. The project is set for completion in June 2026.

21298968

*this image is generated using AI for illustrative purposes only.

Manglam Group, a prominent real estate developer, has made its debut in Mumbai's redevelopment market with the launch of Manglam Rajanigandha, a ₹100 crore project in Borivali (West). This strategic move marks the group's expansion into one of India's most competitive real estate markets.

Project Overview

Feature Details
Project Name Manglam Rajanigandha
Location Borivali (West), Mumbai
Investment ₹100.00 crore
Expected Revenue ₹150.00 crore
Total Area 80,000 sq. ft.
Number of Units 80 two-bedroom apartments
RERA Carpet Area 680 to 776 sq. ft.
Completion Date June 2026

Key Highlights

  • Joint Venture: The project is being developed under Manglam & Karnani Ventures LLP, showcasing a collaborative approach in the competitive Mumbai market.

  • Unit Allocation: 50% of the apartments will be allocated to existing tenants, with the remaining units available for new buyers, balancing the interests of current residents and new homeowners.

  • Amenities: The development will feature various lifestyle amenities, including:

    • Landscaped green zones
    • Fitness center
    • Yoga deck
    • Jogging track
    • Sun deck
  • Exclusive Benefit: All homeowners will receive lifetime membership at the Mandapeshwar Civic Federation Gymkhana, adding value to the property offering.

Market Impact

This project represents Manglam Group's strategic entry into Mumbai's lucrative redevelopment sector. With a track record of 87 completed projects and 32 ongoing developments across India, the group brings significant experience to this new venture.

The Borivali project aligns with the growing trend of redevelopment in Mumbai, where older properties are being transformed to meet modern living standards and maximize land use in space-constrained areas.

Industry Perspective

The ₹100.00 crore investment in Manglam Rajanigandha underscores the potential that developers see in Mumbai's redevelopment market. With expected revenues of ₹150.00 crore, the project highlights the financial viability of such ventures, despite the challenges of working in established urban areas.

As more developers enter the redevelopment space, it could lead to increased competition and potentially more options for homebuyers in Mumbai's western suburbs. The success of this project could pave the way for Manglam Group to undertake more redevelopment projects in the city, further diversifying their portfolio and strengthening their presence in the Mumbai real estate market.

The launch of Manglam Rajanigandha demonstrates the ongoing dynamism in Mumbai's real estate sector, with established players from other regions seeing opportunities for growth and expansion in India's financial capital.

Historical Stock Returns for Mangalam Drugs & Organics

1 Day5 Days1 Month6 Months1 Year5 Years
-1.24%+0.68%-8.14%-12.38%-42.38%-51.49%
Mangalam Drugs & Organics
View in Depthredirect
like20
dislike
More News on Mangalam Drugs & Organics
Explore Other Articles
69.22
-0.87
(-1.24%)